Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920711 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,822
- Enrollment target
NCT01920711 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,822 participants.
The verdict
NCT01920711, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,822 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
Interventions
- DRUG Valsartan
- DRUG LCZ696
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,822 participants |
| Start Date | 2014-07-18 |
| Est. Completion | 2019-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01920711
The ClinicalTrials.gov registry entry for NCT01920711 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,822 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valsartan is the first listed.
NCT01920711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01920711 about?
NCT01920711 is a clinical study titled "Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction". The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
What is the current status of trial NCT01920711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,822 participants. The study started on 2014-07-18. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT01920711?
The interventions under investigation include: Valsartan (DRUG), LCZ696 (DRUG).
Who is sponsoring clinical trial NCT01920711?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.